• Epidermal Growth Factor: From Binding to Translation

  2026-08-19

  Epidermal Growth Factor is more than a cell-growth supplement: it is a controllable perturbation for dissecting receptor signaling, migration, invasion, and mucosal biology. This thought-leadership guide connects recombinant human EGF quality attributes with experimental strategy and translational decision-making.

• NPC1/USP7/p53 Axis in HCC Cholesterol Control

  2026-08-19

  The reference study identifies NPC1 as a multifaceted regulator of hepatocellular carcinoma progression, linking lysosomal cholesterol handling to USP7-dependent destabilization of p53 and SREBP2-associated lipid regulation. Its perturbation-and-rescue design suggests that proliferation, p53 activity, and cholesterol distribution should be evaluated together rather than as isolated phenotypes.

• Exo1 and the Translational Logic of Exocytic Control

  2026-08-18

  Exo1 offers a mechanistically distinct way to interrogate Golgi–ER traffic, ARF1 behavior, and exocytic output. This thought-leadership perspective explains how translational researchers can use Exo1 as a causal perturbation tool when evaluating tumor extracellular vesicle biology, while maintaining a clear boundary between preclinical assay evidence and therapeutic claims.

• Bifendate (DDB) Workflows for Liver Research

  2026-08-18

  Build reproducible liver-cell, lipid-accumulation, autophagy, and drug-interaction assays with Bifendate (DDB). This practical guide connects formulation control and pathway-resolved readouts with CYP3A4 and P-glycoprotein safety workflows.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-08-17

  The reference study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular signal that promotes M2 macrophage polarization through JAK2/STAT6 pathway engagement. Its findings connect a noncoding RNA cargo with an immunosuppressive tumor-microenvironment phenotype and provide a framework for testing pathway dependence in hepatocellular carcinoma models.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-08-17

  A 2025 study found that naturally occurring angiotensin peptide fragments can enhance SARS-CoV-2 spike protein binding to AXL, ACE2, or NRP1 in receptor-specific patterns. The work identifies peptide length and tyrosine modification as important variables, while also showing why these findings require validation beyond antibody-based binding assays.

• PD 173074: Structure and Angiogenesis Inhibition

  2026-08-16

  The reference study established a structural explanation for how PD 173074 inhibits FGFR1 and suppresses FGF- and VEGF-driven angiogenesis. By combining kinase assays, mouse experiments, and 2.5 Å X-ray crystallography, it connected ATP-pocket binding with inhibitor selectivity and provided a framework for interpreting FGFR-directed antiangiogenic research.

• Bifendate (DDB): Dose, Lipids, and Assay Design

  2026-08-15

  Bifendate (DDB) is a hepatoprotection agent whose effects depend strongly on dose, timing, tissue, and assay context. This evidence-led guide reconciles its hepatoprotective applications with high-dose triglyceride elevations and translates those findings into better experimental design.

• Biotin Azide as a Molecular Audit Trail for Fzd5

  2026-08-14

  Biotin Azide enables selective click labeling of alkynylated biomolecules, creating a practical molecular audit trail for studying Fzd5–cholesterol–Wnt signaling. This guide connects reagent chemistry with assay design, controls, enrichment, and interpretation without overstating what the chemistry can prove.

• Protease Inhibitor Cocktail for TP53 Assays

  2026-08-14

  Learn how a Protease Inhibitor Cocktail protects TP53-centered protein assays in DHODH inhibitor studies. This guide connects cancer-metabolism findings with practical choices for Western blotting, co-immunoprecipitation, and EDTA-sensitive workflows.

• Cy3 NHS ester (non-sulfonated): Protocol Guide

  2026-08-13

  Cy3 NHS ester (non-sulfonated) provides an orange fluorescent label for amino groups on proteins, peptides, and nucleic acids when the workflow can tolerate an organic co-solvent. It is not appropriate for aqueous-only labeling or biomolecules that are sensitive to DMSO or DMF; a water-soluble sulfo-Cy3 NHS ester is a better choice in those cases.

• Açaí Extracts: Hepatocyte Cytotoxicity and Induction

  2026-08-13

  Raichura and colleagues evaluated consumer-relevant açaí extracts in sandwich-cultured human hepatocytes and complementary transporter assays. The study found extract-specific, time- and dose-dependent cytotoxicity, but little evidence of induction of major CYP enzymes or drug transporters, refining how botanical–drug interaction risks should be interpreted.

• ARCA Capped mRNA Synthesis with HyperScribe

  2026-08-12

  Discover how the HyperScribe All in One mRNA Synthesis Kit Plus 1 integrates ARCA capping, modified nucleotides, DNase treatment, and poly(A) tailing. This article connects molecular design choices to assay controls and emerging RNA vaccine development evidence.

• CCR7/DUSP1–iCAF Axis in HNSCC Growth

  2026-08-12

  The reference study connects CCR7 signaling in inflammatory cancer-associated fibroblasts with DUSP1 expression, TGF-β1 secretion, and head and neck squamous cell carcinoma behavior. Its integrated single-cell, cell-sorting, genetic perturbation, co-culture, and functional-assay design provides a mechanistic framework for studying how stromal cell states regulate tumor growth.

• SERCA2–CaN/FoxO1/FABP4 Axis in Atherosclerosis

  2026-08-11

  This 2025 study identifies the calcineurin/FoxO1/FABP4 pathway as a mechanistic link between SERCA2 dysfunction, abnormal macrophage lipid handling, foam cell formation, and atherosclerosis. Its combination of a SERCA2 C674S knock-in model, macrophage assays, metabolomics, and pharmacological intervention supports FABP4 inhibition as a strategy for testing how lipid metabolism contributes to vascular inflammation.

16395 records 1/1093 page Next 12345 下5页 Last page